e17604 Background: Relacorilant, a first-in-class selective glucocorticoid receptor antagonist, is being used along with Nab-Paclitaxel for the treatment of Platinum resistant ovarian cancer and has shown better results as compared to Nab-Paclitaxel alone. To systematically evaluate the efficacy and safety of Relacorilant in combination with nab-paclitaxel compared with nab-paclitaxel alone in patients with platinum-resistant ovarian cancer using a GRADE-appraisal meta-analysis of randomized controlled trials. Methods: Embase, PubMed, Cochrane, and ClinicalTrials.gov were searched through December 2025. Four Randomised Controlled Trials assessing the effects of Relacorilant and Nab-Paclitaxel in Platinum resistant ovarian cancer. Pooled analyses of Progression Free Survival (PFS), Overall Survival (OS), Duration of Response (DOR), and Objective Response Rate (ORR), with adverse effects including anemia, neutropenia, and urinary tract infections were performed using random-effects models in R 4.5.2 using “metafor” package. Heterogeneity was quantified using I² statistics. Results: A total of randomized controlled trials evaluating Relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in platinum-resistant ovarian cancer were included. The meta-analysis showed a numerical improvement in progression-free survival (PFS) with combination therapy (pooled mean difference MD 1.26 months, 95% CI 0.15 to 2.38) with low heterogeneity (I² = 0%). Overall survival (OS) also favored Relacorilant-based treatment (MD 1.70 months, 95% CI −2.02 to 5.43), although the effect was not statistically significant. The objective response rate (ORR) was higher in the combination group (risk ratio RR 1.13, 95% CI 0.91 to 1.42, I² = 0%). Patients receiving Relacorilant experienced a longer duration of response (DOR) (MD 1.54 months, 95% CI 0.57 to 2.51, I² = 5%). Safety analyzes revealed no significant difference between the groups in the risk of anemia (RR 1.02, 95% CI 0.66 to 1.59, I² = 8.9%), neutropenia (RR 0.77, 95% CI 0.21 to 2.80, I² = 84.3%), or urinary tract infection (RR 1.00, 95% CI 0.06 to 0.06). Showed. 15.62). Overall variation in safety outcomes ranged from low to substantial. Conclusions: Relacorilant combined with nab-paclitaxel shows modest improvements in clinical efficacy outcomes, including progression-free survival, objective response rate, and duration of response, without a significant increase in treatment-related adverse events, supporting its potential role as a safe and effective therapeutic option for patients with platinum-resistant ovarian cancer, with the overall certainty of evidence ranging from low to moderate depending on the GRADE assessment.
Mirza et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: